PDF(Pubmed)
Abstract：
OBJECTIVE: Alopecia is a common side-effect of chemotherapy and can be extremely distressing to patients. Scalp cooling can be used to reduce hair loss, but the optimal duration of cooling remains unclear. Our aim was to determine whether increasing the duration of scalp cooling improves hair preservation.
METHODS: Patients with HER2-negative, non-metastatic, breast cancer received scalp cooling during adjuvant chemotherapy: three cycles of epirubicin/cyclophosphamide (EC) followed by three cycles of paclitaxel. The patients were randomly assigned to two groups. Group A (n=18) wore a Paxman cooling cap during each infusion and for 30 min post-infusion while Group B (n=19) wore the cap from 30 min before to 2 h after each infusion. All patients were asked to complete a questionnaire recording hair loss/regrowth, adverse events, and quality of life. Success of treatment was defined as <50% hair loss.
RESULTS: The success rates after each of the three cycles did not differ significantly between the two groups (EC: Group A: 40%, Group B: 44%; paclitaxel: Group A: 50%, Group B: 36%; p>0.05). Hair regrowth was significantly higher in Group B at the 8-week follow-up, but not at the 6-month follow-up. Head discomfort affected more patients in Group B than in Group A during the first session (94% vs. 62%, respectively; p=0.039).
CONCLUSIONS: Long duration scalp cooling during chemotherapy might increase patients\' discomfort and does not appear to improve hair preservation.
METHODS: Patients with HER2-negative, non-metastatic, breast cancer received scalp cooling during adjuvant chemotherapy: three cycles of epirubicin/cyclophosphamide (EC) followed by three cycles of paclitaxel. The patients were randomly assigned to two groups. Group A (n=18) wore a Paxman cooling cap during each infusion and for 30 min post-infusion while Group B (n=19) wore the cap from 30 min before to 2 h after each infusion. All patients were asked to complete a questionnaire recording hair loss/regrowth, adverse events, and quality of life. Success of treatment was defined as <50% hair loss.
RESULTS: The success rates after each of the three cycles did not differ significantly between the two groups (EC: Group A: 40%, Group B: 44%; paclitaxel: Group A: 50%, Group B: 36%; p>0.05). Hair regrowth was significantly higher in Group B at the 8-week follow-up, but not at the 6-month follow-up. Head discomfort affected more patients in Group B than in Group A during the first session (94% vs. 62%, respectively; p=0.039).
CONCLUSIONS: Long duration scalp cooling during chemotherapy might increase patients\' discomfort and does not appear to improve hair preservation.
摘要：
目的：脱发是化疗的常见副作用，患者会非常痛苦。头皮冷却可用于减少脱发，但最佳冷却时间仍不清楚。我们的目的是确定增加头皮冷却的持续时间是否可以改善头发保存。
方法：HER2阴性患者，非转移性,乳腺癌在辅助化疗期间接受头皮冷却:3个周期的表柔比星/环磷酰胺(EC),随后3个周期的紫杉醇.将患者随机分为两组。A组（n=18）在每次输注期间和输注后30分钟戴Paxman冷却帽，而B组（n=19）在每次输注前30分钟至2小时戴帽。要求所有患者完成记录脱发/再生的问卷，不良事件,和生活质量。治疗成功定义为<50%脱发。
结果：三个周期中每个周期后的成功率在两组之间没有显着差异（EC：A组：40％，B组：44%；紫杉醇：A组：50%，B组：36%；p>0.05）。在8周的随访中，B组的头发再生明显更高，但不是在6个月的随访中。在第一次会议期间，B组的头部不适影响的患者多于A组（94％与62%,分别为；p=0.039）。
结论：化疗期间长时间的头皮冷却可能会增加患者的不适感，并且似乎不会改善头发保存。
方法：HER2阴性患者，非转移性,乳腺癌在辅助化疗期间接受头皮冷却:3个周期的表柔比星/环磷酰胺(EC),随后3个周期的紫杉醇.将患者随机分为两组。A组（n=18）在每次输注期间和输注后30分钟戴Paxman冷却帽，而B组（n=19）在每次输注前30分钟至2小时戴帽。要求所有患者完成记录脱发/再生的问卷，不良事件,和生活质量。治疗成功定义为<50%脱发。
结果：三个周期中每个周期后的成功率在两组之间没有显着差异（EC：A组：40％，B组：44%；紫杉醇：A组：50%，B组：36%；p>0.05）。在8周的随访中，B组的头发再生明显更高，但不是在6个月的随访中。在第一次会议期间，B组的头部不适影响的患者多于A组（94％与62%,分别为；p=0.039）。
结论：化疗期间长时间的头皮冷却可能会增加患者的不适感，并且似乎不会改善头发保存。
